|
|
GLA-3M-052-LS |
|
Vaxjo ID |
159 |
|
Vaccine Adjuvant Name |
GLA-3M-052-LS |
|
Adjuvant VO ID |
VO_0005385
|
|
Description |
liposome formulation incorporating the toll-like receptor (TLR) 4 agonist, glucopyranosyl lipid adjuvant (GLA), and the TLR7/8 agonist, 3M-052 |
|
Stage of Development |
Research |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
3 |
|
Components |
GLA and 3M-052 combination |
|
Storage |
should be stored at 2-8˚C. |
|
Preparation |
dissolved in chloroform and then evaporated the chloroform, added ammonium phosphate and heated in water bath, then sonication and microfluidization |
|
Function |
innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=58]
Abhyankar et al., 2021: Abhyankar MM, Orr MT, Kinsey R, Sivananthan S, Nafziger AJ, Oakland DN, Young MK, Farr L, Uddin MJ, Leslie JL, Burgess SL, Liang H, De Lima I, Larson E, Guderian JA, Lin S, Kahn A, Ghosh P, Reed S, Tomai MA, Pedersen K, Petri WA Jr, Fox CB. Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy. Frontiers in immunology. 2021; 12; 683157. [PubMed: 34248966].
|
|
